Related Experiment Video
Updated: May 2, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Multi-dimensional Multi-omics Integrative Study to Identify Target Genes for Ischemic Stroke and Related Chronic Pain
Yuanlin Wang1,2, Dan Liu3, Shuai Wang4
1Department of Anesthesiology, Tianjin Medical University General Hospital, Tianjin, China. wyl1996@tmu.edu.cn.
Abstract:
Chronic pain is the most common complications and after-effects for ischemic stroke. Through exploring immune related cell death target genes of ischemic stroke is essential for understanding ischemic stroke and chronic pain complications. Referred to three types of immune related cell deaths' marker genes, mRNA and microRNA transcriptomics data from mice MCAO model were firstly analyzed through multi algorithms. Then, screening common gene with brain chronic pain related dataset. At the single-cell level, we performed immune cell identification and differentially expressional analysis for entire stroke brain environment and pseudo-time analysis for candidate immune cells. Based on GWAS and eQTLs, colocalization analysis, and drug target mendelian randomization methods were used to evaluate causal relationships and drug target effects. Furthermore, to explore spatial characters spatial transcriptomic analysis was conducted. At last, PCR experiments in animal model were conducted. Cell death state is positively correlated with immune infiltration degree. Five core mRNAs, S100a6, Anxa3, Ncf4, Capg, and Arpc1b, and key microRNA, miR-298-5p, were screened as biomarkers for immune related cell death. Among them, S100a6 play key roles. Toll like receptor pathway and CD4+ _γδ T cells were identified as core immune pathway and cells. By comparing with chronic pain GWAS results, S100a6 is screened as promising target. In single-cell analysis, S100a6 participated in CD4+ _γδ T cells differentiation and immune activation on IS. Drug target MR analysis showed that activation of S100a6 was able to decrease 23-54% probabilities to develop into IS. Furtherly, S100a6 gene could balance the negative effects of Cd4 expressed immune cells and protect neuronal function in brain injury spatial zone. In PCR experiment, differentially expressed level of five core genes got proved. In conclusion, our study revealed S100a6 played causal protective roles for ischemic stroke and related chronic pain, could be seen as potential drug target.
Insights
This study identifies S100a6 as a key gene linking ischemic stroke and chronic pain. Activating S100a6 shows protective effects against stroke and reduces pain, suggesting it as a potential drug target.
Area of Science:
- Neuroscience
- Immunology
- Genetics
Background:
- Chronic pain is a common complication following ischemic stroke.
- Understanding immune-related cell death in ischemic stroke is crucial for managing its after-effects.
Purpose of the Study:
- To identify immune-related cell death target genes in ischemic stroke.
- To explore the role of these genes in chronic pain development.
- To evaluate S100a6 as a potential therapeutic target.
Main Methods:
- Analysis of mRNA and microRNA transcriptomics data from a mouse MCAO model.
- Single-cell and spatial transcriptomic analysis of brain tissue.
- Genome-Wide Association Studies (GWAS), eQTLs, and Mendelian randomization (MR) for causal inference and drug target evaluation.
- Polymerase Chain Reaction (PCR) validation in an animal model.
Main Results:
- Five core mRNAs (S100a6, Anxa3, Ncf4, Capg, Arpc1b) and one microRNA (miR-298-5p) were identified as biomarkers for immune-related cell death.
- S100a6 was highlighted for its significant role, involved in CD4+ γδ T cell differentiation and immune activation post-ischemic stroke.
- Activation of S100a6 demonstrated a potential to decrease the probability of developing ischemic stroke by 23-54% and protect neuronal function.
Conclusions:
- S100a6 plays a causal protective role in ischemic stroke and associated chronic pain.
- S100a6 is identified as a promising therapeutic target for ischemic stroke and chronic pain.
- The study elucidates the intricate relationship between cell death, immune response, and neurological complications after stroke.
More Related Videos
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Analgesia and Pain Management
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenomics: Identification of New Drug Targets

